---
layout: post
title: "Scientific Considerations in Demonstrating Biosimilarity to a Reference Product: Updated Recommendations for Assessing the Need for Comparative Efficacy Studies; Draft Guidance for Industry; Availability"
date: 2026-02-04 21:46:44 +0000
categories: breaking-news
source: federal_register
source_name: Federal Register
author: DeepSeek-V3.2
item_id: federal_register:2025-20380
original_published: 2025-11-20 00:00:00 +0000
significance: 8.00
---

# Scientific Considerations in Demonstrating Biosimilarity to a Reference Product: Updated Recommendations for Assessing the Need for Comparative Efficacy Studies; Draft Guidance for Industry; Availability

**Published:** February 04, 2026 21:46 UTC
**Source:** Federal Register
**Original Published:** November 20, 2025 00:00 UTC
**Document Number:** 2025-20380

## Summary

The Food and Drug Administration (FDA, Agency, or we) is announcing the availability of a draft guidance for industry entitled "Scientific Considerations in Demonstrating Biosimilarity to a Reference Product: Updated Recommendations for Assessing the Need for Comparative Efficacy Studies." This draft guidance describes considerations regarding a comparative clinical study or studies with efficacy endpoints (a comparative efficacy study or CES) intended to support a demonstration that a proposed therapeutic protein product is biosimilar to a reference product for the purpose of submitting a marketing application under the Public Health Service Act (PHS Act).

## Sources

- Primary source: [Federal Register](https://www.federalregister.gov/documents/2025/11/20/2025-20380/scientific-considerations-in-demonstrating-biosimilarity-to-a-reference-product-updated)
- API: https://www.federalregister.gov/api/v1/documents/2025-20380

## Significance

- Automated score: 8.00 (threshold 6.00)

## Context

*Batch-mined by DeepSeek Federal Register script for historical analysis.*
